

Evidence for the possible involvement of the P2Y₆ receptor in Ca²⁺ mobilization and insulin secretion in mouse pancreatic islets

Masahiro Ohtani · Jun-ichiro Suzuki ·
Kenneth A. Jacobson · Takami Oka

Received: 9 January 2008 / Accepted: 22 August 2008 / Published online: 11 September 2008
© Springer Science + Business Media B.V. 2008

Abstract Subtypes of purinergic receptors involved in modulation of cytoplasmic calcium ion concentration ([Ca²⁺]_i) and insulin release in mouse pancreatic β-cells were examined in two systems, pancreatic islets in primary culture and beta-TC6 insulinoma cells. Both systems exhibited some physiological responses such as acetylcholine-stimulated [Ca²⁺]_i rise via cytoplasmic Ca²⁺ mobilization. Addition of ATP, ADP, and 2-MeSADP (each 100 μM) transiently increased [Ca²⁺]_i in single islets cultured in the presence of 5.5 mM (normal) glucose. The potent P2Y₁ receptor agonist 2-MeSADP reduced insulin secretion significantly in islets cultured in the presence of high glucose (16.7 mM), whereas a slight stimulation occurred at 5.5 mM glucose. The selective P2Y₆ receptor agonist UDP (200 μM) transiently increased [Ca²⁺]_i and reduced insulin secretion at high glucose, whereas the P2Y_{2/4} receptor agonist UTP and adenosine receptor agonist NECA were inactive. [Ca²⁺]_i transients induced by 2-MeSADP and UDP were antagonized by suramin (100 μM), U73122 (2 μM, PLC inhibitor), and 2-APB (10 or 30 μM, IP₃ receptor antagonist), but neither by staurosporine (1 μM, PKC inhibitor) nor depletion of extracellular Ca²⁺. The effect of 2-MeSADP on [Ca²⁺]_i was also significantly inhibited by MRS2500, a P2Y₁

receptor antagonist. These results suggested that P2Y₁ and P2Y₆ receptor subtypes are involved in Ca²⁺ mobilization from intracellular stores and insulin release in mouse islets. In beta-TC6 cells, ATP, ADP, 2-MeSADP, and UDP transiently elevated [Ca²⁺]_i and slightly decreased insulin secretion at normal glucose, while UTP and NECA were inactive. RT-PCR analysis detected mRNAs of P2Y₁ and P2Y₆, but not P2Y₂ and P2Y₄ receptors.

Keywords Pancreatic islets · P2Y₁ nucleotide receptor · Purines · Pyrimidines · Insulin · Calcium

Abbreviations

ADP	adenosine 5'-diphosphate
2-APB	2-aminoethyl diphenylborinate
2-MeSADP	2-methylthioadenosine 5'-diphosphate
FBS	fetal bovine serum
HEPES	N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
IP ₃	inositol 1,4,5-trisphosphate
MRS2500	2-iodo-N ⁶ -methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate
NECA	5'-N-ethylcarboxamide adenosine phosphate-buffered saline
PBS	phosphate-buffered saline
PKC	protein kinase C
PLC	phospholipase C
RT-PCR	reverse transcription polymerase chain reaction
U73122	1-[6-(((17β)-3-methoxyestra-1,3,5[10]-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione
U73343	1-[6-(((17β)-3-methoxyestra-1,3,5[10]-trien-17-yl)amino)hexyl]-2,5-pyrrolidinedione

M. Ohtani · J.-i. Suzuki · T. Oka (✉)
Research Institute of Pharmaceutical Sciences,
Musashino University,
1-1-20 Shinmachi,
Nishi-Tokyo, Tokyo 202-8585, Japan
e-mail: toka@musashino-u.ac.jp

K. A. Jacobson
Molecular Recognition Section, Laboratory of Bioorganic
Chemistry, National Institutes of Diabetes, Digestive and Kidney
Diseases, National Institutes of Health,
Bethesda, MD 20892, USA

UDP	uridine 5'-diphosphate
UTP	uridine 5'-triphosphate

Introduction

Extracellular ATP and other purine nucleotides serve important functions in regulating metabolism, energy supply, and various cellular activities in many types of cells and tissues [5, 40]. The effects of these agents are mediated through specific P2 receptors that are subdivided into P2X and P2Y families [23, 40]. The P2X receptors are ionotropic, ligand-gated cation channels, whereas P2Y receptors are G protein-coupled receptors [19, 23, 40]. At present, seven P2X and eight P2Y receptor subtypes have been cloned [23]. The role of nucleotides in the endocrine function of the pancreas has been studied. Immunohistochemical studies indicated the presence of P2X₁, P2X₄, P2X₇, P2Y₁, and P2Y₄ receptors in rat and mouse pancreatic islets [8, 9]. Exogenous application of ATP and other nucleotide derivatives has been reported to stimulate insulin secretion in the rat pancreas and isolated rat islets [3, 4, 6, 7, 11, 13, 26, 31, 32]. In addition, stimulation of a P2Y receptor by ATP in rat pancreatic islets has been shown to mobilize Ca²⁺ from internal calcium sources via phospholipase C (PLC) activation and the production of inositol 1,4,5-trisphosphate (IP₃) [4, 35]. The rise in cytosolic Ca²⁺ is a key event in the regulation of insulin secretion in rat pancreatic islets [16]. In addition, stimulation of insulin secretion through a P2Y receptor in rat islets was suggested to be associated with the cAMP/PKA pathway [7]. Enhancement of insulin release by ATP also has been shown in the dog pancreas [35], human islets [12], and several insulinoma cell lines [2, 15, 25, 37]. In addition, ATP caused a transient increase in [Ca²⁺]_i in mouse islet β-cells [16, 41], which was suggested to involve internal calcium stores [41]. In contrast, ATP and its related nucleotide analogues have been shown to inhibit insulin secretion in mouse pancreatic islets [30, 33]. Poulsen et al. [33] have shown that a P2Y₁ receptor and a serine/threonine protein phosphatase calcineurin mediate inhibition of exocytosis of insulin-containing vesicles in the mouse β-cells. Recently, Zhao et al. showed that Ca²⁺ mobilization induced by ATP differed in duration between rat and mouse islet β-cells and suggested that the opposite effect of ATP on insulin release in these two species is due to the difference in the type of calcium ion channel being affected [41]. These results suggest that a P2 receptor subtype and [Ca²⁺]_i are closely associated with control of insulin release. In the present study, we used selective agonists and an antagonist of P2Y receptor subtypes [20, 21] to identify the particular receptor(s) involved in Ca²⁺

mobilization and insulin release in mouse primary pancreatic islets in culture and the mouse β-cell line, beta-TC6. The effect of various inhibitors of signaling molecules was also examined in order to gain insight into the mechanism whereby a P2Y receptor regulates insulin secretion in mouse islet β-cells. The results suggest that P2Y receptor subtypes, P2Y₁ and P2Y₆, are involved in the elevation of [Ca²⁺]_i via Ca²⁺ mobilization from intracellular stores and inhibition of insulin secretion in mouse islet β-cells.

Experimental procedures

Reagents

ATP, UTP, ADP, UDP, NECA, suramin, U73122, U73343, 2-APB, and staurosporine were obtained from the Sigma Chemical Company (St. Louis, MO, USA). 2-MeSADP and MRS2500 were from Tocris Bioscience (Bristol, UK). RPMI 1640 medium, Dulbecco's modified Eagle's medium (DMEM), and penicillin/streptomycin were from Invitrogen Corp. (Carlsbad, CA, USA). Fetal bovine serum (FBS) was from BioWest (Nuaille, France). U73122, U73343, 2-APB, and staurosporine were dissolved in dimethyl sulfoxide (DMSO).

Islet isolation

A pancreas from a male C57 BL/6 mouse (7–12 weeks old) was inflated by injecting 1–2 ml Hank's balanced salt solution (HBSS, pH 7.4, Invitrogen, Carlsbad, CA, USA) containing 20 mM HEPES, 5 mM NaHCO₃, 100 U/ml of penicillin, 100 μg/ml of streptomycin, and 1 mg/ml collagenase type XI (Sigma, St. Louis, MO, USA) and digested for 15–20 min in a water bath at 37°C. The digested tissues were filtered through several metal and nylon meshes with repeated washing with HBSS. Islets were collected on a 40-μm mesh cell strainer (BD Biosciences, Bedford, MA, USA). Pancreatic islets were placed on a 60-mm tissue culture dish (BD Biosciences, Bedford, MA, USA) and cultured for approximately 1 day in RPMI 1640 medium containing 10% FBS, 100 U/ml of penicillin, 100 μg/ml of streptomycin, and 5.5 mM glucose. After initial culture, adequate numbers of islets (100–400) were picked by hand with a micropipette under a stereomicroscope and used for the indicated experiments.

Cell culture

Beta-TC6 cells purchased from ATCC (Manassas, VA, USA) were cultured in DMEM containing 10% FBS, 100 units/ml penicillin, 100 μg/ml streptomycin, and 25 mM glucose in a CO₂ incubator (5% CO₂) at 37°C. The cells were subcultured every week. Cells from passage 10–30 were used for all experiments.

Measurement of $[Ca^{2+}]_i$ changes in single mouse islet and beta-TC6 cells

Thirty islets were transferred into a glass-based dish coated with collagen I (Asahi Techno Glass Corp., Tokyo, Japan) and cultured for 6–10 days in RPMI 1640 medium containing 5.5 mM glucose in 5% CO₂ at 37°C. After removal of the medium, islets were washed once with Krebs/HEPES buffer (NaCl: 129 mM, NaHCO₃: 5 mM, KCl: 4.7 mM, MgSO₄: 1.2 mM, KH₂PO₄: 1.2 mM, CaCl₂: 2.56 mM, and HEPES: 10 mM, adjusted with 5N NaOH to pH 7.4) without glucose and the islets were incubated for 20–30 min at 37°C in 5% CO₂ in 1 ml of the buffer containing 5.5 mM glucose and 3 μM of fura-2 acetoxymethyl ester (Invitrogen, Carlsbad, CA, USA). After one wash with glucose-free buffer, 1 ml of the buffer containing the desired glucose concentrations was added to the dish. Reagent solutions were applied using a pipette. In single islets the temporal change in $[Ca^{2+}]_i$ was monitored using a microscope (Nikon, Tokyo, Japan) equipped with a fluorescence ratio analyzer (Hamamatsu Photonics, Hamamatsu, Japan). The data were expressed as a ratio (340/380 nm) of the fluorescence intensity (emission wavelength at 510 nm) obtained when excited at a 340 or 380 nm wavelength. In Figs. 3 and 5 and Table 1, the $[Ca^{2+}]_i$ response induced by the nucleotide in the absence or presence of an inhibitor was expressed as a change in the ratio (340/380 nm), which was calculated by subtraction of a baseline value from a peak height value. Inhibitors were dissolved in DMSO and mixed well in assay buffer prior to application to the cells. The volume of DMSO per 1 ml buffer was less than 3 μl since 5 μl of DMSO itself increased the baseline of the ratio.

Beta-TC6 cells (2×10^5 cells) were seeded in the glass-based dish and cultured for 1 day in DMEM containing 25 mM glucose in 5% CO₂ at 37°C. After reaching 40–50%

confluency, cells were washed with glucose-free Krebs/HEPES buffer once and loaded with 3 μM fura-2 acetoxymethyl ester for 30–40 min at 37°C in darkness. Then the incubation buffer was removed and replaced with fresh Krebs/HEPES buffer (5.5 mM glucose). Measurement of temporal changes in $[Ca^{2+}]_i$ in an islet-like cluster composed of a few or several beta-TC6 cells was performed with the same method as those mentioned above.

Insulin secretion assay

Isolated islets on a culture dish were preincubated for 60 min at 37°C in 5% CO₂ in Krebs/HEPES buffer containing 3.3 mM glucose. Groups of seven islets were manually transferred to a centrifuge tube and incubated in 1 ml of solution for 60 min at 37°C in the presence of indicated concentrations of glucose, appropriate test agents, and bovine serum albumin (1 mg/ml). After incubation, each tube was centrifuged and the supernatant was stored frozen at –80°C prior to the enzyme immunoassay (EIA) of insulin.

Beta-TC6 cells were seeded in a 24-well plate at a density of 1×10^5 cells/well and were grown at 37°C in the CO₂ incubator (5% CO₂) for 4 days until the 40–50% confluency was reached ($2\text{--}4 \times 10^5$ cells/ml). Cells were washed once with Krebs/HEPES buffer and preincubated for 30 min in glucose-free buffer at 37°C. Then the indicated concentration of glucose was added to each well along with other reagents, and the plate was incubated for 90 min at 37°C in 5% CO₂. At the end of the assay, a supernatant was collected for insulin determination.

Insulin enzyme immunoassay (EIA)

The concentration of insulin released into the assay buffer from the mouse islets and beta-TC6 cells was measured using

Table 1 Effect of a P2Y₁ receptor antagonist MRS2500, a P2 receptor antagonist suramin, a PKC inhibitor staurosporine, and depletion of extracellular Ca²⁺ on (a) 2-MeSADP- or (b) UDP-induced transient $[Ca^{2+}]_i$ rise in the mouse islet and beta-TC6 cells

	+MRS2500		+Suramin	+Staurosporine	No extracellular Ca ²⁺
	10 μM	30 μM	100 μM	1 μM	
a					
	% of control (100 μM 2-MeSADP alone)				
Mouse islet	49±11 (n=6)*	23±8 (n=5)*	15±7 (n=5)*	80±13 (n=3)	80±11 (n=7)
Beta-TC6 cells	35±4 (n=14)*	24±3 (n=16)*	49±10 (n=31)*	113±11 (n=24)	51±12 (n=30)*
b					
	% of control (200 μM UDP alone)				
Mouse islet			11±6 (n=4)*	120±28 (n=5)	112±23 (n=6)
Beta-TC6 cells			51±6 (n=15)*	82±9 (n=32)	65±9 (n=24)*

MRS2500 and suramin were added with the nucleotides simultaneously to the culture of the islet or to beta-TC6 cells in the presence of 5.5 mM glucose. The islet and beta-TC6 cells were preincubated with staurosporine for 20 min (mean±SE)

**P*<0.05

a rat insulin EIA kit (Morinaga Institute of Biological Science, Yokohama, Japan), according to instructions of the company. Each assay was run in duplicate and closely agreeing values (less than 5% variation) were consistently obtained.

Reverse transcription-polymerase chain reaction (RT-PCR) in islets and beta-TC6 cells

The total RNA of the mouse islets (500–1,000 islets) was isolated with RNeasy Mini Kit (Qiagen, Germantown, MD, USA) after genomic DNA was truncated using a QIAshredder (Qiagen, Germantown, MD, USA). Beta-TC6 cells were homogenized in a glass homogenizer on ice and the total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the method described previously [28]. The total RNAs were then treated with DNase I (Ambion, Austin, TX, USA) for 30 min at 37°C to remove genomic DNA. The RNA (islets: 0.1 µg, beta-TC6 cells: 0.5 µg) was reverse transcribed into cDNA using a GeneAmp RNA PCR kit (Applied Biosystems, Branchburg, NJ, USA) and then amplified by PCR with 40 or 30 cycles in the case of islets and beta-TC6 cells, respectively. The oligo primers for mouse P2Y₁, P2Y₂, P2Y₄, and P2Y₆ receptor subtypes and β-actin (internal control) were synthesized commercially (Operon Biotechnology, Tokyo, Japan), according to the sequences for P2Y_{1,2,4,6} receptors [38] and β-actin [22]. These primer sequences were as follows: P2Y₁: sense 5'-TGGCGTGGTGTACCC TCTCAAGTC-3', antisense 5'-ACCGTGCTCGCAAATT CATCGTT-3', P2Y₂: sense 5'-ACCAGCGTGC GGG GAACC-3', antisense 5'-GCATCTCGGGCAAAGCGGA CAAGT-3', P2Y₄: sense 5'-TGCCTCGTGCCCAAC CTCTTCTTT-3', antisense 5'-CAGTTGTTGCGCGCT TAGGTGTGC-3', P2Y₆: sense 5'-CCTGGCACTGGCG GACCTGAT-3', antisense 5'-GGCGGGCCATGCGA CAATAAC-3', and β-actin: sense 5'-GATGACGA TATCGCTGCGCTGGTCGTC-3', antisense 5'-GACCCT CAGGGCATCGGAACCGCTCG-3'. Annealing temperatures for P2Y₁, P2Y₂, P2Y₄, P2Y₆, and β-actin in PCR were

57°C, 59°C, 60°C, 59°C and 65°C, respectively. Contamination of genomic DNA in the total RNAs was examined by performing RT-PCR in the absence of a reverse transcriptase. Electrophoresis of the amplified cDNA was performed on a 1.5% agarose gel containing ethidium bromide and the cDNA was visualized using a UV transilluminator at 302 nm.

Statistics

Data were expressed as mean ± SE. Statistical significance was evaluated by Student's *t* test. A *P* value < 0.05 was statistically significant.

Results

Effect of purinergic agonists on [Ca²⁺]_i in mouse single islets and beta-TC6 cells

We first examined the effect of high concentrations of glucose and acetylcholine (ACh), which are well-known potent stimulators of [Ca²⁺]_i in the primary islet in culture [10, 14]. Both the increase of the glucose concentration from 5.5 mM to 16.7 mM (Fig. 1a) and ACh at 100 µM (Fig. 1b) induced an increase in [Ca²⁺]_i over a control that was incubated in the presence of 5.5 mM glucose without ACh. These results were consistent with previous findings [14].

We next examined the effect of various purinergic compounds on [Ca²⁺]_i in mouse single islets in culture. As shown in Fig. 2a, ATP at 100 µM induced a transient increase in [Ca²⁺]_i, but it had little effect at 1 and 10 µM (data not shown). In addition, both a synthetic analogue of ADP, 2-MeSADP and ADP at 100 µM (data not shown), which are P2Y_{1/12} receptor agonists, and a P2Y₆ receptor-selective agonist UDP at 200 µM stimulated [Ca²⁺]_i (Fig. 2b,c). We found that UDP had little effect at 100 µM and that UTP, which has a high affinity for P2Y₂ and P2Y₄ receptors, did not elevate [Ca²⁺]_i even at 200 µM (data not shown). A selective adenosine receptor agonist, NECA (200 µM) [34],




Fig. 1 Effect of a high concentration of glucose and acetylcholine (ACh) on [Ca²⁺]_i in a single mouse islet in culture. Glucose at 16.7 mM (G16.7, **a**) and ACh at 100 µM (**b**) were added to the mouse islet in the presence of 5.5 mM glucose (G5.5) at the time indicated by

the bar. The change in [Ca²⁺]_i was monitored for 30 min using excitation at 340 and 380 nm and emission at 510 nm, and the bar indicates exposure to the indicated nucleotide. Each experiment was repeated 3 times




Fig. 2 Effect of ATP, 2-MeSADP, and UDP on $[Ca^{2+}]_i$ in a single mouse islet and beta-TC6 cells in culture. ATP at 100 μ M (a, d), 2-MeSADP at 100 μ M (b, e), and UDP at 200 μ M (c, f) were added to the mouse single islet (a–c) and beta-TC6 cells (d–f) in the presence of 5.5 mM glucose at the time indicated by the bar. In beta-TC6 cells, $[Ca^{2+}]_i$ rise occurring in each islet-like cluster composed of a few or

several cells (9–10 clusters) is shown with overlapping different colors. The change in $[Ca^{2+}]_i$ was monitored for 20 min using excitation at 340 and 380 nm and emission at 510 nm, and the bar indicates exposure to the indicated nucleotide. Each experiment was repeated 7–15 times

also showed no effect (data not shown), suggesting that ATP or ADP did not raise $[Ca^{2+}]_i$ via adenosine receptors through metabolic conversion to adenosine. To determine whether $[Ca^{2+}]_i$ rises induced by the nucleotides were mediated through purinergic receptors, we examined the effect of a nonspecific P2 receptor antagonist, suramin, and a highly specific P2Y₁ receptor antagonist, MRS2500 [39], in the mouse islet. Suramin (100 μ M) significantly blocked both 2-MeSADP- (100 μ M) and UDP (200 μ M)-induced transient

$[Ca^{2+}]_i$ elevations, suggesting that these responses were mediated via the P2 receptor (Table 1). MRS2500 at 30 μ M significantly inhibited the $[Ca^{2+}]_i$ rise induced by 2-MeSADP (100 μ M) in the islet, whereas it had a smaller inhibitory effect at 10 μ M (Table 1). The above results indicated that P2Y₁ and P2Y₆ receptors were functional in mouse pancreatic islets in culture.

ATP, 2-MeSADP, and ADP (data not shown) each at 100 μ M and UDP at 200 μ M also induced an increase in




Fig. 3 The effect of purinergic compounds on $[Ca^{2+}]_i$ in a mouse single islet in culture and beta-TC6 cells. The following compounds were tested: ATP (100 μ M), 2-MeSADP (100 μ M), ADP (100 μ M), and UDP (200 μ M). The effect of the nucleotides on $[Ca^{2+}]_i$ is shown

as % of the peak response induced by ATP (100 μ M) in the mouse single islet in culture (a) and beta-TC6 cells (b) in the presence of 5.5 mM glucose. Each bar represents the mean \pm SE (n=7–15 in a and n=24–54 in b)




Fig. 4 Effect of the PLC inhibitor U73122 and the IP₃ receptor antagonist 2-APB on 2-MeSADP- or UDP-induced [Ca²⁺]_i rise in a single mouse islet in culture. U73122 at 2 μM (a, c) and 2-APB at 30 μM (b) or 10 μM (d) were added to the islet 20 min prior to the addition of the

nucleotides. The change in [Ca²⁺]_i was monitored for 20 min using excitation at both 340 and 380 nm and emission at 510 nm, and the bar indicates exposure to the indicated nucleotide or the inhibitor. Each experiment was repeated 3–4 times

[Ca²⁺]_i in mouse insulinoma beta-TC6 cells (Fig. 2d–f), suggesting that the nucleotide-induced [Ca²⁺]_i increase in pancreatic islets was attributable, at least in part, to the response of β-cells in the islet. As shown in Table 1, these

effects both by 2-MeSADP and UDP were significantly blocked by suramin (100 μM). The effect of 2-MeSADP was also significantly inhibited by MRS2500 (10 or 30 μM).




Fig. 5 Effect of the PLC blocker U73122 and the IP₃ receptor antagonist 2-APB on 2-MeSADP- or UDP-induced [Ca²⁺]_i rise in beta-TC6 cells. Cells were incubated in the presence of either 2 μM U73122 (a, c) or 30 μM 2-APB (b, d) for 20 min prior to addition of

the nucleotides. The results are expressed as a change in ratio (calculated by subtraction of a baseline value from a peak height value). Each bar represents the mean ± SE (*n* = 16–32). **P* < 0.05 in comparison to control in the absence of nucleotides




Fig. 6 Effect of 2-MeSADP and UDP on insulin secretion in mouse islets in culture. The islets were incubated in Krebs/HEPES buffer (pH 7.4) containing 5.5 mM (G5.5, **a**) or 16.7 mM glucose (G16.7, **b**) in the presence of 100 μ M 2-MeSADP or 200 μ M UDP for 60 min at 37°C. Each bar represents the mean \pm SE ($n=8$ in **a** and $n=10$ in **b**). * $P<0.05$ in comparison to control in the absence of nucleotides

In order to determine quantitatively the effect of the nucleotides on $[Ca^{2+}]_i$, a peak height induced by each nucleotide was expressed as % of that induced by 100 μ M ATP. The effect of 2-MeSADP on $[Ca^{2+}]_i$ appeared to be almost the same as that of ATP in both the islet and beta-TC6 cells, while the effect of UDP even at 200 μ M was smaller than that of ATP (Fig. 3a,b).

$[Ca^{2+}]_i$ transients induced by P2Y₁ and P2Y₆ receptor activations are mediated through intracellular Ca^{2+} mobilization

It has been demonstrated that both P2Y₁ and P2Y₆ receptors are Gq protein-coupled receptors and their stimulation results in the activation of PLC, which produces the second messengers IP₃ and diacylglycerol (DG) [23, 40]. Then IP₃ induces Ca^{2+} mobilization from intracellular stores in the endoplasmic reticulum and protein kinase C (PKC) is activated by DG. In order to gain insight into the

mechanism of Ca^{2+} mobilization induced by the nucleotides in islets, we examined the effect of U73122, a PLC inhibitor and an IP₃ receptor inhibitor 2-APB. As shown in Fig. 4a and c, U73122 at 2 μ M significantly inhibited 2-MeSADP- (100 μ M) and UDP (200 μ M)-induced $[Ca^{2+}]_i$ increases, whereas U73343, an inactive analogue of U73122, did not (data not shown). 2-APB also significantly inhibited $[Ca^{2+}]_i$ rises induced by 2-MeSADP at 30 μ M (Fig. 4b) and UDP at 10 μ M (Fig. 4d). The transient $[Ca^{2+}]_i$ rises induced by both the nucleotides in the islet were still observed when the extracellular Ca^{2+} was depleted (Table 1). By contrast, a PKC inhibitor staurosporine showed no significant inhibitory effect. These results suggested the involvement of intracellular Ca^{2+} stores in the $[Ca^{2+}]_i$ elevation induced by the P2Y₁ and P2Y₆ receptor activation, whereas the PKC did not appear to play a role. Similar inhibitory effects were observed in beta-TC6 cells (Fig. 5a–d and Table 1). However, $[Ca^{2+}]_i$ responses induced by both 2-MeSADP and UDP were significantly inhibited in the absence of extracellular Ca^{2+} in beta-TC6 cells (Table 1). It was possible that Ca^{2+} influx through a Ca^{2+} channel partly contributed to the $[Ca^{2+}]_i$ elevation induced by stimulation of P2Y₁ or P2Y₆ receptor in beta-TC6 cells.


Inhibitory effect of nucleotides on insulin secretion in mouse islets and beta-TC6 cells

Both 2-MeSADP (100 μ M) and UDP (200 μ M) enhanced glucose (5.5 mM)-induced insulin secretion in mouse islets by 15 and 19%, respectively (Fig. 6a), however, these effects were not statistically significant. In the presence of a high concentration of glucose (16.7 mM glucose), however, 2-MeSADP and UDP produced significant inhibitions of insulin secretion ($P<0.05$) by 39 and 43%, respectively (Fig. 6b). In beta-TC6 cells cultured in the presence of 5.5 mM glucose insulin secretion was also reduced by 2-MeSADP at 100 μ M and UDP at 200 μ M, but these effects were smaller (2-MeSADP: $81 \pm 4\%$ compared with 5.5 mM glucose alone, $n=8$; UDP: $84 \pm 9\%$, $n=8$). Among the nucleotides tested (ATP, 2-MeSADP, ADP, and UDP), only the effect of 2-MeSADP was statistically significant.

P2Y₁ and P2Y₆ receptor mRNA expression in mouse islets and beta-TC6 cells

The above pharmacological studies suggested that P2Y₁ and P2Y₆ receptors were present and functional in both the mouse islets and beta-TC6 cells. We next examined whether P2Y₁, P2Y₂, P2Y₄, and P2Y₆ receptor mRNAs were expressed by RT-PCR. As shown in Fig. 7a and b, the P2Y₁ and P2Y₆ receptor mRNAs were present, whereas expression of P2Y₂ and P2Y₄ receptor mRNAs was not detectable in both the mouse islets and beta-TC6 cells. As a

Fig. 7 RT-PCR analysis of P2Y receptor subtype mRNAs in mouse islets and beta-TC6 cells. PCR reactions were performed by 40 cycles in the islets (a) and by 30 cycles in beta-TC6 cells (b) with specific primers for each P2Y receptor subtype. The expected PCR product lengths for P2Y₁, P2Y₂, P2Y₄, P2Y₆, and β -actin were 410, 440, 499, 452, and 778 bp, respectively. Reverse transcription was performed with (+) or without (-) a reverse transcriptase to assess genomic DNA contamination. M shows a 100-bp DNA ladder



positive control, expression of P2Y₂ and P2Y₄ mRNAs in the mouse brain was confirmed with the specific primers (data not shown), indicating that failure to detect these receptor mRNAs in β -cells was not due to the primer sequences. The estimated sizes of the PCR products of P2Y₁ and P2Y₆ receptors were the same in both the islets and beta-TC6 cells.

Discussion

In the rat and mouse pancreas, P2X₁, P2X₄, P2X₇, P2Y₁, P2Y₂, and P2Y₄ receptors were detected by immunohistochemical studies [8, 9]. Recently, Garcia et al. reported by RT-PCR and the Western blot analyses that P2Y₁, P2Y₂, P2Y₄, P2Y₆, and P2Y₁₂ receptors were expressed in rat insulinoma INS-1 cells [27]. In the present study we found that several P2Y receptor agonists elevated $[Ca^{2+}]_i$ in mouse islets in culture in the presence of 5.5 mM glucose. The findings that ATP, ADP, 2-MeSADP, and UDP but not UTP induced $[Ca^{2+}]_i$ rises suggested the involvement of the P2Y receptor, especially P2Y₁ and P2Y₆ receptors. RT-PCR analysis also indicated that P2Y₁ and P2Y₆ receptors were present in the islets. Our results are consistent with the view that the P2Y₁ receptor can regulate $[Ca^{2+}]_i$ in pancreatic β -cells [14, 31, 39] and insulinoma [37]. In addition to the P2Y₁ receptor, we found that UDP, a selective activator of the P2Y₆ receptor, elicited a transient $[Ca^{2+}]_i$ increase and inhibition of insulin release. These results suggested the possible involvement of the P2Y₆ receptor in the regulation of insulin secretion in the mouse islet. However, since UDP produced its effect at the relatively high concentration of 200 μ M, we could not rule out the possibility that the effect of UDP may be mediated via other

receptors. In our assay system, UDP-induced $[Ca^{2+}]_i$ rises were blocked by 1 μ M MRS2179 in mouse islets (data not shown). There are several possibilities for the blockade. The first possibility is that various indirect effects could be produced when the nucleotides were incubated for a long time with the cells, since $[Ca^{2+}]_i$ measurements were performed under the static non-perfusion assay conditions. The second one is that the P2Y₁ receptor couples with the P2Y₆ receptor to form a heterodimer and therefore the UDP effect is influenced by the antagonist, since some functional recombinant heteromeric P2X receptors have been reported [20].

An earlier electrophysiological study also presented evidence indicating that suppression of Ca^{2+} -dependent exocytosis of insulin-containing granules was mediated via the P2Y₁ receptor in mouse primary islet β -cells [33]. It is also noteworthy that insulin secretion was significantly elevated in islets isolated from P2Y₁-deficient mice (P2Y₁ $-/-$) in comparison to those from wild-type animals [24], suggesting the involvement of the P2Y₁ receptor in inhibiting insulin secretion in the mouse islets. Since insulin secretory granules contain ATP [18] and ATP is co-released with insulin by pancreatic β -cells, it is possible that ATP exerts a negative control over insulin secretion in a feedback manner [33].

P2Y receptor activation enhanced moderate or high glucose-induced insulin release in rat islets, whereas such an enhancement was not observed in the presence of a low glucose concentration [4, 7, 11, 13, 31, 32]. It was also shown that pulsatile insulin secretion induced by high glucose in rat islets was enhanced in the presence of MRS2179 without affecting $[Ca^{2+}]_i$ oscillation [17, 36]. These results indicated that the P2Y₁ receptor plays a role in the regulation of insulin secretion in rat islets as well as in

mouse islets. In the present study, we found that stimulation of the P2Y₁ or P2Y₆ receptor resulted in a significant inhibition of high glucose (16.7 mM)-induced insulin secretion, while they showed a slight potentiation (not significant) at a normal glucose level (5.5 mM). The decreased insulin secretion was consistent with those amounts observed in the presence of stimulatory concentrations of glucose (10 or 15 mM) [30, 33]. Recently, we found that both ADP and UDP exhibited inhibitory effects on a sustained elevation and oscillations of [Ca²⁺]_i induced by high glucose (16.7 mM) in the islet (preliminary data). Taken together with the present results, it is suggested that the transient increases in [Ca²⁺]_i are associated with the slight stimulation, whereas the inhibitory effect on glucose-induced [Ca²⁺]_i rises is related to the significant inhibition of insulin release in mouse islets.

Very recently, Parandeh et al. reported that UDPβS, a selective agonist for the P2Y₆ receptor, stimulated insulin release in mouse islets *in vitro* [29]. Its stimulatory effect was observed at concentrations as low as 10 nM and reached the maximum at concentrations ranging from 100 nM to 1 μM that differed depending on the glucose concentration. On the other hand, in the present study we employed a high concentration of UDP, 200 μM, that increased [Ca²⁺]_i in mouse islets and found that it inhibited insulin secretion. It is clear that the opposite effect of UDP on insulin secretion is related to its concentration used in the two studies. Since we do not know the extracellular concentration of UDP during insulin secretion in mouse islets, it is not possible to evaluate the physiological significance of UDP effects observed at the two different concentrations. The possibility exists that UDP may produce its dual effects on insulin secretion in a concentration-dependent manner, i.e., a stimulatory effect at low concentrations and an inhibitory effect at high concentrations. However, we cannot rule out the possibility that the inhibitory effect of UDP at a high concentration is pharmacological and is mediated via other receptors.

Both P2Y₁ and P2Y₆ receptors are coupled to the Gq protein [23, 40]. We found that the effect of 2-MeSADP and UDP on [Ca²⁺]_i was inhibited by inhibitors of PLC and the IP₃ receptor and still persisted in the absence of extracellular Ca²⁺ in the medium. These results suggest that stimulation of the P2Y₁ or P2Y₆ receptor induces the [Ca²⁺]_i elevation by mobilizing from intracellular stores through the activation of a PLC/IP₃ pathway in the mouse islets. In a previous report, Zhao et al. showed that Ca²⁺ mobilization induced by ATP differed in duration between rat and mouse islet β-cells and suggested that the observed opposite pattern of insulin release, i.e., stimulation and inhibition between these two species, is due to the difference in the type of a store-operated calcium ion channel being involved [41].

It has been shown that protein kinases such as PKC and PKA or protein phosphatases play a crucial role in the P2Y receptor-mediated regulation of exocytosis in the islet β-cells [1, 10, 33]. Previous studies showed that activation of a cAMP/PKA pathway by the P2Y receptor enhanced insulin release in the rat [7], whereas activation of serine/threonine protein phosphatase calcineurin inhibited exocytosis of insulin-containing granules in the mouse system [33]. These findings suggested that activation of protein kinases and phosphatases can play a key role in controlling exocytosis of insulin-containing granules in the islet β-cells. In the present study, however, we found that the PKC inhibitor staurosporine had no effect on 2-MeSADP- or UDP-induced [Ca²⁺]_i rises. Thus, PKC did not appear to contribute to the generation of the nucleotide-induced [Ca²⁺]_i rises in the mouse islets.

The islet contains α-, β-, and δ-cells, and only β-cells produce and secrete insulin [14]. In order to examine whether the effect of 2-MeSADP and UDP on [Ca²⁺]_i was related to β-cells in the islet, we employed beta-TC6 insulinoma cells as another experimental β-cell model. We found that beta-TC6 cells, like the pancreatic islets, responded to the purinergic nucleotides in terms of [Ca²⁺]_i and insulin secretion. The response occurred in the presence of 5.5 mM glucose. Our previous study showed that these cells had a lower threshold for glucose so that 5.5 mM glucose elicited the maximal insulin secretion in these insulinoma cells [28]. We also found by RT-PCR analysis that the P2Y₁ and P2Y₆ receptors also were expressed in beta-TC6 cells. There is no clear evidence that a functional P2 receptor is present in other types of cells such as α-cells in the islet. These results suggested that the effect of nucleotides on [Ca²⁺]_i and insulin secretion in the mouse islet can be attributable to β-cells.

In summary, we present evidence indicating that the mouse islets and beta-TC6 cells possess a P2Y₁ or P2Y₆ receptor and respond to the purinergic agonists by increasing [Ca²⁺]_i via intracellular Ca²⁺ mobilization and modulation of insulin secretion. These purinergic receptors, especially the P2Y₆ receptor, may play a role as autocrine regulators of insulin release and may serve as a target for treatment of diabetes mellitus.

Acknowledgements This work was supported partly by MEXT, HAITEKU and a Grant-in-aid for Scientific Research from the Japan Society for the Promotion of Science and by the NIDDK Intramural Program of NIH.

References

1. Ämmälä C, Eliasson L, Bokvist K, Berggren PO, Honkanen RE, Sjöholm Å et al (1994) Activation of protein kinases and

- inhibition of protein phosphatases play a central role in the regulation of exocytosis in mouse pancreatic beta cells. *Proc Natl Acad Sci USA* 91:4343–4347. doi:10.1073/pnas.91.10.4343
2. Arkhammar P, Hallberg A, Kindmark H, Nilsson T, Rorsman P, Berggren PO (1990) Extracellular ATP increases cytoplasmic free Ca^{2+} concentration in clonal insulin-producing RINm5F cells. A mechanism involving direct interaction with both release and refilling of the inositol 1,4,5-trisphosphate-sensitive Ca^{2+} pool. *Biochem J* 265:203–211
 3. Bertrand G, Chapal J, Puech R, Loubatières-Mariani MM (1991) Adenosine-5'-O-(2-thiodiphosphate) is a potent agonist at P2 purinoceptors mediating insulin secretion from perfused rat pancreas. *Br J Pharmacol* 102:627–630
 4. Blachier F, Malaisse WJ (1988) Effect of exogenous ATP upon inositol phosphate production, cationic fluxes and insulin release in pancreatic islet cells. *Biochim Biophys Acta* 970:222–229. doi:10.1016/0167-4889(88)90182-6
 5. Burnstock G (1993) Physiological and pathological roles of purines: an update. *Drug Dev Res* 28:195–206. doi:10.1002/ddr.430280303
 6. Chapal J, Hillarie-Buys D, Bertrand G, Pujalte D, Petit P, Loubatières-Miriani MM (1997) Comparative effects of adenosine-5'-triphosphate and related analogues on insulin secretion from the rat pancreas. *Fundam Clin Pharmacol* 11:537–545
 7. Chevassus H, Roig A, Belloc C, Lajoix AD, Broca C, Manteghetti M et al (2002) P2Y receptor activation enhances insulin release from pancreatic β -cells by triggering the cyclic AMP/protein kinase A pathway. *Naunyn Schmiedebergs Arch Pharmacol* 366:464–469. doi:10.1007/s00210-002-0620-4
 8. Coutinho-Silva R, Parson M, Robson T, Burnstock G (2001) Change in expression of P2 receptors in rat and mouse pancreas during development and aging. *Cell Tissue Res* 306:373–383. doi:10.1007/s004410100458
 9. Coutinho-Silva R, Parson M, Robson T, Lincoln J, Burnstock G (2003) P2X and P2Y purinoceptor expression in pancreas from streptozotocin-diabetic rats. *Mol Cell Endocrinol* 204:141–154. doi:10.1016/S0303-7207(03)00003-0
 10. Doyle ME, Egan JM (2003) Pharmacological agents that directly modulate insulin secretion. *Pharmacol Rev* 55:105–131. doi:10.1124/pr.55.1.7
 11. Farret A, Vignaud M, Dietz S, Vignon J, Petit P, Gross R (2004) P2Y purinergic potentiation of glucose-induced insulin secretion and pancreatic β -cell metabolism. *Diabetes* 53:S63–S66. doi:10.2337/diabetes.53.suppl_3.S63
 12. Fernandez-Alvarez J, Hillarie-Buys D, Loubatières-Miriani MM, Gomis R, Petit P (2001) P2 receptor agonists stimulate insulin release from human pancreatic islets. *Pancreas* 22:69–71. doi:10.1097/00006676-200101000-00012
 13. Geschwind JF, Hiriart M, Clennon MC, Najafi H, Corkey BE, Matschinsky FM et al (1989) Selective activation of Ca^{2+} influx by extracellular ATP in a pancreatic β -cell line (HIT). *Biochim Biophys Acta* 1012:107–115. doi:10.1016/0167-4889(89)90018-9
 14. Gilon P, Henquin JC (2001) Mechanisms and physiological significance of the cholinergic control of pancreatic β -cell function. *Endocr Rev* 22:565–604. doi:10.1210/er.22.5.565
 15. Hauge-Evans AC, Squires PE, Belin VD, Roderigo-Milne H, Ramracheya RD, Persaud SJ et al (2002) Role of adenine nucleotides in insulin secretion from MIN6 pseudoislets. *Mol Cell Endocrinol* 191:167–176. doi:10.1016/S0303-7207(02)00051-5
 16. Hellman B, Dansk H, Grapengiesser E (2004) Pancreatic β -cells communicate via intermittent release of ATP. *Am J Physiol Endocrinol Metab* 286:E759–E765. doi:10.1152/ajpendo.00452.2003
 17. Hellman B, Gylfe E, Grapengiesser E, Lund P-E, Berts A (1992) Cytoplasmic Ca^{2+} oscillations in pancreatic β -cells. *Biochim Biophys Acta* 1113:295–305
 18. Hutton JC, Penn EJ, Pashavaria M (1983) Low-molecular-weight constituents of isolated insulin secretory granules. Bivalent cations, adenine nucleotides and inorganic phosphate. *Biochem J* 210:297–305
 19. Jacobson KA, Costanzi S, Ohno M, Joshi BV, Besada P, Xu B et al (2004) Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. *Curr Top Med Chem* 4:805–819. doi:10.2174/1568026043450961
 20. Jacobson KA, Jarvis MF, Williams M (2002) Purine and pyrimidine (P2) receptors as drug targets. *J Med Chem* 45:4057–4093. doi:10.1021/jm020046y
 21. Jonkers FC, Henquin JC (2001) Measurements of cytoplasmic Ca^{2+} in islet cell clusters show that glucose rapidly recruits β -cells and gradually increases the individual cell response. *Diabetes* 50:540–550. doi:10.2337/diabetes.50.3.540
 22. Knaack D, Fiore DM, Surana M, Leiser M, Laurance M, Fusco-DeMane D et al (1994) Clonal insulinoma cell line that stably maintains correct glucose responsiveness. *Diabetes* 43:1413–1417. doi:10.2337/diabetes.43.12.1413
 23. Lazarowski ER, Boucher RC, Harden TK (2003) Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. *Mol Pharmacol* 64:785–795. doi:10.1124/mol.64.4.785
 24. Léon C, Freund M, Latchoumanin O, Farret A, Petit P, Cazenave J-P et al (2005) The P2Y₁ receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice. *Purinergic Signal* 1:145–151. doi:10.1007/s11302-005-6209-x
 25. Li G, Milani D, Dunne MJ, Pralong W-F, Theler JM, Petersen OH et al (1991) Extracellular ATP causes Ca^{2+} -dependent and -independent insulin secretion in RINm5F cells. Phospholipase C mediates Ca^{2+} mobilization but not Ca^{2+} influx and membrane depolarization. *J Biol Chem* 266:3449–3457
 26. Loubatières-Mariani MM, Chapal J, Lignon F, Valette G (1979) Structural specificity of nucleotides for insulin secretory action from the isolated perfused rat pancreas. *Eur J Pharmacol* 59:277–286. doi:10.1016/0014-2999(79)90291-7
 27. Lugo-Garcia L, Filhol R, Lajoix AD, Gross R, Petit P, Vignon J (2007) Expression of purinergic P2Y receptor subtypes by INS-1 insulinoma beta-cells: a molecular and binding characterization. *Eur J Pharmacol* 568:54–60. doi:10.1016/j.ejphar.2007.04.012
 28. Ohtani M, Oka T, Badyuk M, Xiao Y, Kellar KJ, Daly JW (2006) Mouse β -TC6 insulinoma cells: high expression of functional $\alpha 3\beta 4$ nicotinic receptors mediating membrane potential, intracellular calcium, and insulin release. *Mol Pharmacol* 69:899–907
 29. Parandeh F, Abaraviciene SM, Amisten S, Erlinge D, Salehi A (2008) Uridine diphosphate (UDP) stimulates insulin secretion by activation of P2Y₆ receptors. *Biochem Biophys Res Commun* 370:499–503. doi:10.1016/j.bbrc.2008.03.119
 30. Petit P, Bertrand G, Schmeer W, Henquin JC (1989) Effects of extracellular adenosine nucleotides on the electrical, ionic and secretory events in mouse pancreatic β -cells. *Br J Pharmacol* 98:875–882
 31. Petit P, Manteghetti M, Puech R, Loubatières-Mariani MM (1987) ATP and phosphate-modified adenine nucleotide analogues. Effects on insulin secretion and calcium uptake. *Biochem Pharmacol* 36:377–380. doi:10.1016/0006-2952(87)90297-8
 32. Petit P, Hillarie-Buys D, Manteghetti M, Debrus S, Chapal J, Loubatières-Mariani MM (1998) Evidence for two different types of P2 receptors stimulating insulin secretion from pancreatic B cell. *Br J Pharmacol* 125:1368–1374. doi:10.1038/sj.bjp.0702214
 33. Poulsen CR, Bokvist K, Olsen HL, Høy M, Capito K, Gilon P (1999) Multiple sites of purinergic control of insulin secretion in mouse pancreatic β -cells. *Diabetes* 48:2171–2181. doi:10.2337/diabetes.48.11.2171

34. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. *Pharmacol Rev* 50:413–492
35. Ribes G, Bertrand G, Petit P, Loubatieres-Mariani MM (1988) Effects of 2-methylthio ATP on insulin secretion in the dog in vivo. *Eur J Pharmacol* 155:171–174. doi:10.1016/0014-2999(88)90418-9
36. Salehi A, Quader SS, Grapengiesser E, Hellman B (2005) Inhibition of purinoceptors amplifies glucose-stimulated insulin release with removal of its pulsatility. *Diabetes* 54:2126–2131. doi:10.2337/diabetes.54.7.2126
37. Verspohl EJ, Johannwille B, Waheed A, Neye H (2002) Effect of purinergic agonists and antagonists on insulin secretion from INS-1 cells (insulinoma cell line) and rat pancreatic islets. *Can J Physiol Pharmacol* 80:562–568. doi:10.1139/y02-079
38. Vial C, Evans RJ (2002) P2X1 receptor-deficient mice establish the native P2X receptor and a P2Y6-like receptor in arteries. *Mol Pharmacol* 62:1438–1445. doi:10.1124/mol.62.6.1438
39. Von Kügelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. *Pharmacol Ther* 110:415–432. doi:10.1016/j.pharmthera.2005.08.014
40. Williams M, Jarvis MF (2000) Purinergic and pyrimidinergic receptors as potential drug targets. *Biochem Pharmacol* 59:1173–1185. doi:10.1016/S0006-2952(99)00341-X
41. Zhao YF, Xu R, Hernandez M, Zhu Y, Chen C (2003) Distinct intracellular Ca²⁺ response to extracellular adenosine triphosphate in pancreatic β -cells in rats and mice. *Endocrine* 22:185–192. doi:10.1385/ENDO:22:3:185